Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study

NCT04194957 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT04194957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04194957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Unknown status
Start date
January 15, 2020
Completion date
January 31, 2021
Enrollment
1,440 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms